Meeting
2021 ASCO Annual Meeting
Noninferiority study evaluating dexamethasone (DEX)-sparing regimens administered with NEPA, a fixed combination of netupitant and palonosetron, for the prevention of chemotherapy-induced nausea and vomiting (CINV) caused by high-dose cisplatin.
Authors
Luigi Celio
Oncology Unit, ASST del Garda, Desenzano del Garda Hospital, Brescia, Italy
Luigi Celio , Erminio Bonizzoni , Emilio Bria
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT04201769
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 12093)
DOI
10.1200/JCO.2021.39.15_suppl.12093
Abstract #
12093
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy of olanzapine, netupitant, and palonosetron in controlling nausea and vomiting associated with highly emetogenic chemotherapy in patients with breast cancer (OLNEPA).
First Author: Camilla Vieira de Reboucas
Poster
2022 ASCO Annual Meeting
Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).
First Author: Rudolph M. Navari
Poster
2021 ASCO Annual Meeting
Assessing duration of breakthrough chemotherapy-induced nausea and vomiting (CINV): A pooled study analysis of NEPA versus aprepitant.
First Author: Rudolph M. Navari
Poster
2017 ASCO Annual Meeting
Phase III study of NEPA, a fixed combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV).
First Author: Li Zhang